Login / Signup

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.

Akihiko InoueShutaro IsokawaNorio OtaniShinichi Ishimatsu
Published in: Critical care (London, England) (2020)
Keyphrases
  • sars cov
  • combination therapy